Genetic Disruption of Myostatin Reduces the Development of Proatherogenic Dyslipidemia and Atherogenic Lesions In Ldlr Null Mice
AUTOR(ES)
Tu, Powen
FONTE
American Diabetes Association
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2712781Documentos Relacionados
- Erythropoietin reduces the expression of myostatin in mdx dystrophic mice
- Association between atherogenic dyslipidemia and fournier’s gangrene
- Evaluation and management of atherogenic dyslipidemia: beyond low-density lipoprotein cholesterol
- PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice
- The potential influence of atherogenic dyslipidemia on the severity of chronic Chagas heart disease